Development of live attenuated influenza vaccines against pandemic influenza strains

被引:40
作者
Coelingh, Kathleen L. [1 ]
Luke, Catherine J. [2 ]
Jin, Hong [3 ]
Talaat, Kawsar R. [4 ]
机构
[1] AstraZeneca, Gaithersburg, MD 20878 USA
[2] NIH, Bethesda, MD 20892 USA
[3] MedImmune, Mountain View, CA 94043 USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA
基金
美国国家卫生研究院;
关键词
intranasal influenza vaccine; LAIV; pandemic influenza vaccine; ANN-ARBOR STRAIN; CELLULAR IMMUNE-RESPONSES; PHASE-I TRIAL; VIRUS VACCINE; H5N1; INFLUENZA; POSTMARKETING EVALUATION; CHILDREN; HEALTHY; SAFETY; PROTECTION;
D O I
10.1586/14760584.2014.922417
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Avian and animal influenza viruses can sporadically transmit to humans, causing outbreaks of varying severity. In some cases, further human-to-human virus transmission does not occur, and the outbreak in humans is limited. In other cases, sustained human-to-human transmission occurs, resulting in worldwide influenza pandemics. Preparation for future pandemics is an important global public health goal. A key objective of preparedness is to gain an understanding of how to design, test, and manufacture effective vaccines that could be stockpiled for use in a pandemic. This review summarizes results of an ongoing collaboration to produce, characterize, and clinically test a library of live attenuated influenza vaccine strains (based on Ann Arbor attenuated Type A strain) containing protective antigens from influenza viruses considered to be of high pandemic potential.
引用
收藏
页码:855 / 871
页数:17
相关论文
共 51 条
  • [1] The role of nasal IgA in children vaccinated with live attenuated influenza vaccine
    Ambrose, Christopher S.
    Wu, Xionghua
    Jones, Taff
    Mallory, Raburn M.
    [J]. VACCINE, 2012, 30 (48) : 6794 - 6801
  • [2] The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies
    Ambrose, Christopher S.
    Wu, Xionghua
    Knuf, Markus
    Wutzler, Peter
    [J]. VACCINE, 2012, 30 (05) : 886 - 892
  • [3] An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years
    Ambrose, Christopher S.
    Yi, Tingting
    Falloon, Judith
    [J]. INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2011, 5 (06) : 389 - 397
  • [4] Ambrose CS, 2008, INFLUENZA OTHER RESP, V2, P193, DOI 10.1111/j.1750-2659.2008.00056.x
  • [5] [Anonymous], 2013, QUADR INFL VACC LIV
  • [6] Bandell A, 2011, EXPERT REV VACCINES, V10, P1131, DOI [10.1586/ERV.11.73, 10.1586/erv.11.73]
  • [7] A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age
    Baxter, Roger
    Toback, Seth L.
    Sifakis, Frangiscos
    Hansen, John
    Bartlett, Joan
    Aukes, Laurie
    Lewis, Ned
    Wu, Xionghua
    Ambrose, Christopher S.
    [J]. VACCINE, 2012, 30 (20) : 3053 - 3060
  • [8] A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age
    Baxter, Roger
    Toback, Seth L.
    Sifakis, Frangiscos
    Hansen, John
    Bartlett, Joan
    Aukes, Laurie
    Lewis, Ned
    Wu, Xionghua
    Ambrose, Christopher S.
    [J]. VACCINE, 2012, 30 (19) : 2989 - 2998
  • [9] Efficacy of a Single Dose of Live Attenuated Influenza Vaccine in Previously Unvaccinated Children: A Post Hoc Analysis of Three Studies of Children Aged 2 to 6 Years
    Block, Stan L.
    Toback, Seth L.
    Yi, Tingting
    Ambrose, Christopher S.
    [J]. CLINICAL THERAPEUTICS, 2009, 31 (10) : 2140 - 2147
  • [10] Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate
    Chen, H
    Matsuoka, Y
    Swayne, D
    Chen, Q
    Cox, NJ
    Murphy, BR
    Subbarao, K
    [J]. VACCINE, 2003, 21 (27-30) : 4430 - 4436